Site notifications

Sub menu

GMP clearance Sponsor Information Dashboard (SID)

SID provides industry with regular updates about the backlog reduction, actual processing times, existing workloads, requesting prioritisation and other key messages for GMP clearance applications.

Last updated

We welcome any feedback you may have on the SID. Please send this to GMPclearance@health.gov.au.

The below data is from 1 July 2026 and will be updated every 4 to 6 weeks to ensure it remains current.

Backlog reduction progress

The graphs below illustrate the trend of GMP Clearance applications over time. Further details on actual numbers can be read from opening the drop-down menu under each graph.

Figure 1 shows the trend of the total number of CV applications in our lodgement queue over the past 12 months. The total number of CV applications steadily reduced in 2025, with a steep drop at the beginning of Q3 2025 due to the backlog reduction strategy. Since the backlog reduction strategy was introduced on 1 July 2025, the rate of reduction has also increased as expected. Since the end of Q2 2025, the total number of applications reduced from 2156 applications to 1055 to date, which equates to a reduction of - 52%.

Figure 1 - Total number of CV applications pending assessment between 1 June 2025 and 1 July 2026

Figure 1 - Total number of CV applications pending assessment between 1 June 2025 and 1 July 2026

Figure 1 shows a line graph detailing the total number of Good Manufacturing Practice (GMP) Compliance Verification (CV) clearance applications between end of Q2 2025 and Q2 2026.

The vertical axis represents the total number of GMP clearance applications within the TGA’s application lodgement system.

The horizontal axis represents the date broken down by quarter and year.

The graph starts at 2156 applications in Q2 2025 and ends at 1055 applications in Q2 2026, illustrating a steady decrease in the backlog over the year.

Figure 2 shows the trend of applications in our CV streams over the past year with each line representing a different stream.

Both the Non-Sterile Active Pharmaceutical Ingredient (NS-API) and Non-Sterile Finished Product (NS-FP) streams have significantly reduced over the past year. More recently, the rate of reduction in the NS- FP stream has increased following the allocation of additional resources, whilst the rate of reduction in the NS-API stream has increased. There is now a consistent reduction in the Sterile Finished Product (ST-FP) stream whilst the Sterile API stream (S-API) has remained steady.

Figure 2 - number of CV applications in lodgement by stream between 1 June 2025 and 1 July 2026

Figure 2 - number of CV applications in lodgement by stream between 1 June 2025 and 1 July 2026

Figure 2 shows a line graph detailing the number of Good Manufacturing Practice (GMP) clearance compliance verification applications pending assessment in each stream between Q2 2025 and Q2 2026.

The vertical axis represents the total number of GMP clearance applications within the TGA’s application lodgement system.

The horizontal axis represents the date broken down by quarter and year.

There are four lines represented within the graph.

The line with a diamond marker at the top of the graph represents non-sterile active pharmaceutical ingredient compliance verification applications. This shows steady application numbers around ~650 up until the end of June 2025, followed by a sharp decrease to ~500 by August 2025. These numbers further decrease to ~250 by 1 July 2026.

The next line with a square marker represents non-sterile finished product compliance verification applications. The line shows a consistent decrease in application numbers from ~590 in Q2 2025 to ~309 by 1 July 2026.

The third line with a triangle marker represents sterile finished product compliance verification applications. This shows that there was a decrease in application numbers from ~350 to ~273 by 1 July 2026.

The bottom line with a circle marker represents sterile active pharmaceutical ingredient compliance verification applications. This shows that there has been a slight decrease from ~180 to ~160 within the last year.

Workload volumes

Figure 3 shows a snapshot of all GMP Clearance applications in the system at different stages of evaluation or queue categories. The largest number remains 'complete' applications in lodgement queues ready for evaluation (This includes both MRA and CV application types). The total number of all applications in the system on 1 July 2026 was 1201. This a reduction of 85 since the June update.

Figure 3 - total number of GMP clearance applications and the applications status as of 1 July 2026

Figure 3 - total number of GMP clearance applications and the applications status as of 1 July 2026

Figure 3 shows a bar graph detailing total numbers of Good Manufacturing Practice (GMP) clearance applications and the applications status.

The vertical axis represents the number of applications.

The horizontal axis represents the status of the applications.

There are nine bars:

The first bar from the left side of the graph represents complete applications awaiting assessment, there are 569 applications represented, which remains steady since June.

The second bar represents assessments in progress, that is applications currently being considered by evaluators, there are 240 applications represented,  a decrease of 61 applications since June.

The third bar represents administrative applications awaiting assessment, this includes updates for manufacturer names and addresses as well as other application types, there are 85 applications represented, a decrease by 13 applications since June.

The fourth bar represents applications awaiting payment, there are 69 applications represented, a decrease of 6 applications since June.

The fifth bar represents applications awaiting receipt (screening), there are 59 applications represented, an increase of 3 applications since June.

The sixth bar represents applications which are currently on hold (typically for GMP non-compliance investigations), there are 56 applications represented, an increase of 1 since June. 

The seventh bar represents incomplete applications. There are 48 applications represented, which remains steady since June.

The eighth bar represents letter of access applications, there are 45 applications represented, an increase of 3 applications since June.

The ninth bar on the far right of the graph represents extensions. There are 30 applications represented, a decrease of 11 applications since June.

CV processing timeframes (Rolling 2-year data)

Figure 4 shows the percentile ranges for application processing timeframes for applications submitted in the last two years for each CV stream, measured in TGA working days.

This graph has been re-introduced but now excludes data from application submitted more than two years ago. This gives Industry a more realistic snapshot of expected processing timeframes for future applications.

Each bar is divided into percentiles, which represent the percentage of applications completed within a certain number of days. For example, the 50th percentile means half of the applications were completed in that time or less. The percentiles build on each other - for example, the 50% mark includes all applications completed within the 10% and 25% ranges as well.

It is expected these percentiles will fluctuate as we return to a steady state and continue to manage requests for prioritisation.

Figure 4 - percentage of CV applications submitted and completed within the past two years as of 1 July 2026

Figure 4 - percentage of CV applications submitted and completed within the past two years as of 1 July 2026

ST FP: sterile finished product applications
ST API: sterile active pharmaceutical ingredient applications
NS FP: non-sterile finished product applications
NS API: non-sterile active pharmaceutical ingredient applications

Figure 4 shows a bar graph detailing percentages of Good Manufacturing Practice (GMP) clearance compliance verification applications completed within specified TGA working days during the past two years.

The vertical axis represents the compliance verification application streams.

The horizontal axis represents the number of days taken by the TGA to complete applications.

There are four bars, the first bar from the bottom of the graph represents non-sterile active pharmaceutical ingredient compliance verification applications. This shows that:

  • ten percent of applications are completed within 12 days,
  • twenty five percent of applications are completed within 44 days,
  • fifty percent of applications are completed within 85 days,
  • seventy five percent of applications are completed within 180 days 
  • ninety percent of applications are completed within 247 days.

The second bar represents non-sterile finished product compliance verification applications. This shows that:

  • ten percent of applications are completed within 35 days
  • twenty five percent of applications are completed within 100 days
  • fifty percent of applications are completed within 186 days
  • seventy five percent of applications are completed within 302 days
  • ninety percent of applications are completed within 370 days

The third bar represents sterile active pharmaceutical ingredient compliance verification applications. This shows that:

  • ten percent of applications are completed within 7 day
  • twenty five percent of applications are completed within 22 days
  • fifty percent of applications are completed within 135 days
  • seventy five percent of applications are completed within 212 days 
  • ninety percent of applications are completed within 308 days

The fourth bar represents sterile finished product compliance verification applications. This shows that:

  • ten percent of applications are completed within 35 days
  • twenty five percent of applications are completed within 114 days
  • fifty percent of applications are completed within 208 days
  • seventy five percent of applications are completed within 308 days 
  • ninety percent of applications are completed within 343 days

MRA processing timeframes (rolling 3 monthly data)

The figures below provide an overview of the target and actual processing times for certain application types, measured in TGA working days. The actual processing time applies for 90 percent of applications completed within the last 3 months.

  • 30

    Target MRA application processing time

  • 25

    Actual MRA application processing time

CV application annual volumes

Figure 5 shows a snapshot of GMP Clearance CV applications received and completed within the last four years since 2023. Overall, there is a general decline in applications received over time. In 2025, we completed 1704 CV applications, which is 57% more than received that year as we implemented the backlog reduction strategy and had more evaluators signed off for CV applications. The total number of applications completed year to date as of 1 July 2026 is 903.
 

Figure 5 - total number of GMP clearance CV applications received and completed per year as of 1 July 2026

Figure 5 - total number of GMP clearance CV applications received and completed per year as of 1 July 2026

Figure 5 shows a clustered column bar graph comparing the number of Good Manufacturing Practice (GMP) clearance compliance verification applications received and completed across four years (2023-2026).

The vertical axis represents the number of applications.

The horizontal axis represents the calendar year.

There are four pairs of bars, with each pair representing a single year. Within each pair:

  • the black bar represents applications received, and
  • the grey bar represents applications completed.

The first pair of bars (2023) shows that:

  • approximately 1,450 applications were received, and
  • approximately 800 applications were completed.

The second pair of bars (2024) shows that:

  • approximately 1,350 applications were received, and
  • approximately 950 applications were completed.

The third pair of bars (2025) shows that:

  • approximately 1,100 applications were received, and
  • approximately 1,700 applications were completed.

The fourth pair of bars (2026) shows that:

  • approximately 530 applications were received, and
  • approximately 900 applications were completed.

Overall, the graph shows a decreasing trend in applications received over time, while applications completed increase significantly in 2025 with the implementation of backlog reduction strategies.

Application Quality (rolling 6-monthly data)

The figures below provide an overview of how many applications required a Request For Information (RFI) or were incomplete at the time of submission.

  • 12 % of 381 applications

    Percentage of Mutual Recognition Agreement (MRA) applications requiring an RFI

  • 32 % of 903 applications

    Percentage of incomplete CV applications

  • 67 % of 903 applications

    Percentage of Compliance Verification (CV) applications requiring an RFI

  • 25 % of 65 applications

    Percentage of TGA certificate applications requiring an RFI

  • 60 % of 62 applications

    Percentage of applications using a letter of access (LoA) requiring an RFI

The above data tells us that approximately 1 in every 3 CV applications is submitted incomplete. This adds pressure onto TGA staff and causes significant delays in processing times. We encourage sponsors to work with their manufacturers to ensure all required evidence is provided at the point of submission where possible.

Prioritisation requests

We will continue to process effective applications as quickly as possible. Medicine shortages remain a high priority for us, and we will continue to process these when sponsors have provided the required information.

Please note that we will liaise internally with the medicine shortages team to verify requests and seek additional information such as supply and market data.

For any request for prioritisation, you must provide the required information outlined below via email:

  • The product name and existing ARTG number (where applicable)
  • The category of medicine (Complementary, Non-prescription, Prescription etc.)
  • The product submission type and submission number and any applicable milestone dates (for example, priority review pathway or NCE, PM-XXXX-XXXXX-X-X etc.)
  • For variations, you need to provide information about the change as certain changes made by manufacturers may require additional GMP evaluation.
  • For requests linked to reportable medicines, the medicines shortage notification number (for example MS-XXXX-XX-XXXXX-X)
  • Any other information to help us understand the urgency of the situation. For example, existing stock levels or run-out dates, negative effect on patients or business etc.

Featured notices

Related resources

Product types
Topics